New Data Show Certain Demographics are Denied Cholesterol-Lowering Medication More Often
Medication access remains a hurdle for many patients, especially those prescribed cholesterol-lowering PCSK9 inhibitors.
Poll: Health Plan Delays are “Unreasonable,” Dangerous for Heart Patients
Heart disease patients, providers, caregivers and stakeholders agree: Health plan policies that delay access to life-saving medication are unacceptable.
PCSK9 Inhibitors: South Carolina
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in South Carolina from January 2017 through December 2017. Of national health plans that received at least 50 claims for PCSK9 inhibitors, the following had the highest rates of rejection: Tricare Military Health Svc Sys – 59% BCBS South Carolina – 54% Express […]
New Data, Same Access Challenges for Heart Patients
The risk of death may be lower for certain patients taking cholesterol-lowering PCSK9 inhibitors, new research shows. But how many patients will actually be able to realize the drugs’ benefits? Research Results The latest research found that patients had a significantly lower risk of major cardiovascular events when taking PCSK9 inhibitors. Announced at this weekend’s […]
IfPA Report Cards: 1 in 4 Heart Patients Can’t Access Innovative Rx
Health plans said “no” to one in every four Americans whose doctor prescribed a cholesterol-lowering PCSK9 inhibitor in 2017. And that, according to the Institute for Patient Access’ new access report cards, means that more than 78,000 heart patients went without medicine that could have reduced their risk of heart attack and stroke. National Report […]
PCSK9 Inhibitors: National
A national data supplier reviewed PCSK9 inhibitor claims for Medicare, Medicaid, Medicaid managed care, and commercial managed care organizations across the nation from January 2017 through December 2017. Of national health plans that received at least 2,000 claims for PCSK9 inhibitors, the following had the highest rates of rejection: • Federal Employee Benefit Plan – […]
PCSK9 Inhibitors: Alabama
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Alabama from January 2017 through December 2017. Of health plans that received at least 100 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • BCBS Alabama – 48% • CVS Health – 45% • Express Scripts – 37% […]
PCSK9 Inhibitors: California
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in California from January 2017 through December 2017. Of health plans that received at least 400 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • BS of CA – 60% • Express Scripts – 48% • Centene – 46% […]
PCSK9 Inhibitors: Florida
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Florida from January 2017 through December 2017. Of health plans that received at least 300 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • Federal Employee Benefit Plan – 84% • Florida Blue – 51% • Tricare Military […]
PCSK9 Inhibitors: Texas
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Texas from January 2017 through December 2017. Of health plans that received at least 400 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • Federal Employee Benefit Plan – 82% • Tricare Military Health SVC SYS – 44% […]
